Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 73Nivolumab 27atezolizumab 15Docetaxel 10Cyclophosphamide 10cemiplimab 9Ipilimumab 9Paclitaxel 8Interleukin-2 8Biopsy 7fludarabine 6durvalumab 6avelumab 6Taxes 6Specimen Handling 6epacadostat 5Magnetic Resonance Spectroscopy 5Immune Checkpoint Inhibitors 5Gemcitabine 5Drug Therapy 5Cisplatin 5Carboplatin 5spartalizumab 4Radiotherapy 4Radiosurgery 4Pemetrexed 4Cetuximab 4utomilumab 3trametinib 3poly ICLC 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × nanocis × Head & Neck × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡